News Minimalist logo

Weight-loss drugs like Ozempic drive $21B sales in 2023

The Conversation — April 1, 2024, 08:00 PM UTC

Summary: The rise of weight-loss drugs like Ozempic, originally developed for type 2 diabetes, has generated A$21 billion in sales in 2023. Novo Nordisk's semaglutide, marketed as Ozempic, leads to around 15% weight loss. Mounjaro, a new drug targeting GIP and GLP-1 receptors, has shown 18% weight loss. Clinical trials of Eli Lilly's retatrutide have demonstrated a weight loss of around 24%. These drugs must be injected due to their large peptide molecules. Pfizer and Eli Lilly are developing oral GLP-1 receptor-targeting drugs.

Full article

Article metrics

The article metrics are deprecated.

I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.

Timeline:

  1. [5.0]
    Biocon Ltd enters weight loss drug market amid expiring patents (Mint)
    110d

    ScoresSource
  2. [4.0]
    New weight-loss drugs may surpass Wegovy's effectiveness (Irish Medical Times)
    112d
    Source
  3. [2.7]
    Semaglutides' weight loss benefits may be overestimated (New York Post )
    117d
    Source
  4. [6.1]
    Ozempic weight-loss drug gaining popularity despite side effects (The Conversation)
    117d

    ScoresSource
  5. [3.5]
    Ozempic may impact pregnancy despite birth control use (WFLA)
    122d
    Source
  6. [5.3]
    Medicare spending on diabetes drugs increased significantly in 2022 (CNN)
    122d

    ScoresSource